| Next 10 |
Ad
PSTV Articles PLUS THERAPEUTICS Inc.
home / stock / pstv / pstv articles
Articles | PLUS THERAPEUTICS Inc. (NYSE:PSTV)
-
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around...
-
PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday. The stock continues to gain after reporting third-quarter financial ...
-
Gainers Cellectis S.A. (NASDAQ: CLLS) shares surged 152% to $2.43 in pre-market trading. Cellectis reported strategic collaboration and investment ...
-
AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compan...
-
AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compan...
-
Biocept Inc (NASDAQ: BIOC) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. In a document filed with ...
-
AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
The Dow Jones closed lower by close to 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around...
Stock Information
Get PSTV Alerts
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
Ad
-
Median overall survival (mOS) in 15 patients with recurrent glioblastoma (rGBM) from the Phase 2 study is 13 months, which is 63% better than current standard of care (bevacizumab monotherapy) of 8 months; 9 of the 15 patients remain alive Median progression free survival (mPFS) is 11 mon...
-
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
-
AUSTIN, Texas, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced it ...